scholarly journals Nonoperative Management of Venous Ulcers and the Emerging Role of Bioengineered Skin Substitutes

2000 ◽  
Vol Volume 13 (Number 3) ◽  
pp. 0069-0080
Author(s):  
Everett Y. Lam ◽  
Gregory L. Moneta
2021 ◽  
Vol 8 (11) ◽  
pp. 148
Author(s):  
Mina Aleemardani ◽  
Michael Zivojin Trikić ◽  
Nicola Helen Green ◽  
Frederik Claeyssens

There is a distinct boundary between the dermis and epidermis in the human skin called the basement membrane, a dense collagen network that creates undulations of the dermal–epidermal junction (DEJ). The DEJ plays multiple roles in skin homeostasis and function, namely, enhancing the adhesion and physical interlock of the layers, creating niches for epidermal stem cells, regulating the cellular microenvironment, and providing a physical boundary layer between fibroblasts and keratinocytes. However, the primary role of the DEJ has been determined as skin integrity; there are still aspects of it that are poorly investigated. Tissue engineering (TE) has evolved promising skin regeneration strategies and already developed TE scaffolds for clinical use. However, the currently available skin TE equivalents neglect to replicate the DEJ anatomical structures. The emergent ability to produce increasingly complex scaffolds for skin TE will enable the development of closer physical and physiological mimics to natural skin; it also allows researchers to study the DEJ effect on cell function. Few studies have created patterned substrates that could mimic the human DEJ to explore their significance. Here, we first review the DEJ roles and then critically discuss the TE strategies to create the DEJ undulating structure and their effects. New approaches in this field could be instrumental for improving bioengineered skin substitutes, creating 3D engineered skin, identifying pathological mechanisms, and producing and screening drugs.


2019 ◽  
Vol 8 (12) ◽  
pp. 2083 ◽  
Author(s):  
Francesco Urciuolo ◽  
Costantino Casale ◽  
Giorgia Imparato ◽  
Paolo A. Netti

The formation of severe scars still represents the result of the closure process of extended and deep skin wounds. To address this issue, different bioengineered skin substitutes have been developed but a general consensus regarding their effectiveness has not been achieved yet. It will be shown that bioengineered skin substitutes, although representing a valid alternative to autografting, induce skin cells in repairing the wound rather than guiding a regeneration process. Repaired skin differs from regenerated skin, showing high contracture, loss of sensitivity, impaired pigmentation and absence of cutaneous adnexa (i.e., hair follicles and sweat glands). This leads to significant mobility and aesthetic concerns, making the development of more effective bioengineered skin models a current need. The objective of this review is to determine the limitations of either commercially available or investigational bioengineered skin substitutes and how advanced skin tissue engineering strategies can be improved in order to completely restore skin functions after severe wounds.


Burns ◽  
2007 ◽  
Vol 33 (8) ◽  
pp. 946-957 ◽  
Author(s):  
Clarabelle Pham ◽  
John Greenwood ◽  
Heather Cleland ◽  
Peter Woodruff ◽  
Guy Maddern

2016 ◽  
Vol 66 ◽  
pp. 130-137 ◽  
Author(s):  
A.R. Sadeghi ◽  
S. Nokhasteh ◽  
A.M. Molavi ◽  
M. Khorsand-Ghayeni ◽  
H. Naderi-Meshkin ◽  
...  

2013 ◽  
Vol 21 (2) ◽  
pp. 194-210 ◽  
Author(s):  
Nicholas S. Greaves ◽  
Syed A. Iqbal ◽  
Mohamed Baguneid ◽  
Ardeshir Bayat

2018 ◽  
Vol 9 (3) ◽  
pp. 291-295
Author(s):  
Teli Bhavuray ◽  
◽  
Mundada Ashishkumar B. ◽  
Avula Sreekant ◽  
Ganeshan Karthick ◽  
...  

1986 ◽  
Vol 1 (3) ◽  
pp. 197-203 ◽  
Author(s):  
G. T. Layer ◽  
M. C. Stacey ◽  
K. G. Burnand

A report on an interim analysis of a large placebo-controlled double-blind randomized clinical trial evaluating the role of fibrinolytic enhancement in the management of venous ulceration is described. Seventy-five patients with venous ulcers have entered the trial and fulfilled the inclusion criteria. The ulcers were treated by a standard regime of compression bandaging combined with the oral administration of placebo or stanozolol (Stromba; Sterling Research Laboratories, Guildford). Treatment was continued until healing, and the healing times were compared between the two groups. Sixty-five per cent of ulcers treated with stanozolol have healed and 61.5 % on placebo. There was no overall difference in the healing times of patients treated with stanozolol or placebo. When the healing times were analysed after stratification into initial size, there was no difference between the ulcers of small (less than 2 cm2) or large (greater than 5 cm2) initial area, but for the ulcers between 2 and 5 cm2 there was a trend in favour of improved healing for those ulcers treated with stanozolol ( P = 0.13, log rank test).


2004 ◽  
Vol 37 (01) ◽  
pp. 28-33
Author(s):  
K. Murali Mohan Reddy ◽  
D. Mukunda Reddy

ABSTRACTMost of the venous ulcers will heal with the treatment of primary venous problem. But a few patients will have refractory, recurrent chronic venous ulcers causing inconvenience to the patients in terms of loss of productive working hours. There is no standard method available for treatment of this chronic problem. Our modality of treatment includes wide excision of ulcer, ligation of incompetent perforators and coverage of defect with well vascularized tissue by free tissue transfer. We have analyzed this form of treatment in five patients with satisfactory result.


Sign in / Sign up

Export Citation Format

Share Document